

**Bulletin from the extraordinary general meeting in Magle Chemoswed Holding AB (publ) on the 14<sup>th</sup> of December 2021**

At the extraordinary General Meeting in Magle Chemoswed Holding AB, held on December 14<sup>th</sup>, 2021, by way of postal voting procedure the main resolutions passed were the following:

- EGM resolved that the Board of Directors continue to consist of six (6) members and one (1) deputy member;
- Martin Lidgard was elected as new member of the Board until the end of general meeting 2022;
- EGM resolved that remuneration to the Board of Directors decided at the annual general meeting 2021 shall be applied and distributed pro rata to the new member- Martin Lidgard.

Minutes from the Extraordinary General Meeting with complete resolutions will be made available at <https://maglegroup.com/>

**For Further Information, please contact**

Justin Pierce, CEO

Phone: +46 (0)70 593 58 21

Email: [Justin.Pierce@maglechemoswed.com](mailto:Justin.Pierce@maglechemoswed.com)

**About us**

We are Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that serves companies in the pharmaceutical and medical device industry on a contract basis. We provide comprehensive services from product development through product manufacturing and we pride ourselves in coming up with solutions to complex healthcare challenges. Together with our customers, we take innovations from idea to product. Learn more on [www.maglechemoswed.com](http://www.maglechemoswed.com) and <https://maglegroup.com/>

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.